Literature DB >> 20670935

The reciprocal regulation of gamma-synuclein and IGF-I receptor expression creates a circuit that modulates IGF-I signaling.

Minjing Li1, Yancun Yin, Hui Hua, Xiangming Sun, Ting Luo, Jiao Wang, Yangfu Jiang.   

Abstract

Insulin-like growth factor (IGF) system plays important roles in carcinogenesis and maintenance of the malignant phenotype. Signaling through the IGF-I receptor (IGF-IR) has been shown to stimulate the growth and motility of a wide range of cancer cells. γ-synuclein (SNCG) is primarily expressed in peripheral neurons but also overexpressed in various cancer cells. Overexpression of SNCG correlates with tumor progression. In the present study we demonstrated a reciprocal regulation of IGF-I signaling and SNCG expression. IGF-I induced SNCG expression in various cancer cells. IGF-IR knockdown or IGF-IR inhibitor repressed SNCG expression. Both phosphatidylinositol 3-kinase and mitogen-activated protein kinase were involved in IGF-I induction of SNCG expression. Interestingly, SNCG knockdown led to proteasomal degradation of IGF-IR, thereby decreasing the steady-state levels of IGF-IR. Silencing of SNCG resulted in a decrease in ligand-induced phosphorylation of IGF-IR and its downstream signaling components, including insulin receptor substrate (IRS), Akt, and ERK1/2. Strikingly, SNCG physically interacted with IGF-IR and IRS-2. Silencing of IRS-2 impaired the interaction between SNCG and IGF-IR. Finally, SNCG knockdown suppressed IGF-I-induced cell proliferation and migration. These data reveal that SNCG and IGF-IR are mutually regulated by each other. SNCG blockade may suppress IGF-I-induced cell proliferation and migration. Conversely, IGF-IR inhibitors may be of utility in suppressing the aberrant expression of SNCG in cancer cells and thereby block its pro-tumor effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20670935      PMCID: PMC2945541          DOI: 10.1074/jbc.M110.131698

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  Involvement of RHO GTPases and ERK in synuclein-gamma enhanced cancer cell motility.

Authors:  Zhong-Zong Pan; Wendy Bruening; Andrew K Godwin
Journal:  Int J Oncol       Date:  2006-11       Impact factor: 5.650

2.  Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.

Authors:  J Ma; M N Pollak; E Giovannucci; J M Chan; Y Tao; C H Hennekens; M J Stampfer
Journal:  J Natl Cancer Inst       Date:  1999-04-07       Impact factor: 13.506

3.  Adult-onset growth hormone and insulin-like growth factor I deficiency reduces neoplastic disease, modifies age-related pathology, and increases life span.

Authors:  William E Sonntag; Christy S Carter; Yuji Ikeno; Kari Ekenstedt; Cathy S Carlson; Richard F Loeser; Shilla Chakrabarty; Shuko Lee; Colleen Bennett; Rhonda Ingram; Tracy Moore; Melinda Ramsey
Journal:  Endocrinology       Date:  2005-03-24       Impact factor: 4.736

4.  Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers.

Authors:  Haiyan Liu; Wei Liu; Yinwei Wu; Yue Zhou; Rong Xue; Chan Luo; Lan Wang; Wei Zhao; Jian-Dong Jiang; Jingwen Liu
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

5.  Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration.

Authors:  Wei Zhao; Haiyan Liu; Wei Liu; Yinwei Wu; Wei Chen; Bin Jiang; Yue Zhou; Rong Xue; Chan Luo; Lan Wang; Jian-Dong Jiang; Jingwen Liu
Journal:  Int J Oncol       Date:  2006-05       Impact factor: 5.650

6.  Differential expression of multiple anti-apoptotic proteins in epidermis of IGF-1 transgenic mice as revealed by 2-dimensional gel electrophoresis/mass spectrometry analysis.

Authors:  Jianjun Shen; Penny K Riggs; Sean C Hensley; Lisa J Schroeder; Angelina R Traner; Kelli J Kochan; Maria D Person; John DiGiovanni
Journal:  Mol Carcinog       Date:  2007-05       Impact factor: 4.784

Review 7.  Disrupting insulin-like growth factor signaling as a potential cancer therapy.

Authors:  Deepali Sachdev; Douglas Yee
Journal:  Mol Cancer Ther       Date:  2007-01       Impact factor: 6.261

8.  Stimulation of breast cancer invasion and metastasis by synuclein gamma.

Authors:  T Jia; Y E Liu; J Liu; Y E Shi
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

9.  Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer.

Authors:  Jianping Guo; Chengchao Shou; Lin Meng; Beihai Jiang; Bin Dong; Lihua Yao; Yuntao Xie; Jianzhi Zhang; Yiding Chen; Daniel R Budman; Yuenian Eric Shi
Journal:  Int J Cancer       Date:  2007-09-15       Impact factor: 7.396

Review 10.  GRP78 induction in cancer: therapeutic and prognostic implications.

Authors:  Amy S Lee
Journal:  Cancer Res       Date:  2007-04-15       Impact factor: 12.701

View more
  13 in total

1.  SILAC-based proteomic analysis to investigate the impact of amyloid precursor protein expression in neuronal-like B103 cells.

Authors:  Dale Chaput; Lisa Hornbeck Kirouac; Harris Bell-Temin; Stanley M Stevens; Jaya Padmanabhan
Journal:  Electrophoresis       Date:  2012-12       Impact factor: 3.535

2.  Metastasis regulation by PPARD expression in cancer cells.

Authors:  Xiangsheng Zuo; Weiguo Xu; Min Xu; Rui Tian; Micheline J Moussalli; Fei Mao; Xiaofeng Zheng; Jing Wang; Jeffrey S Morris; Mihai Gagea; Cathy Eng; Scott Kopetz; Dipen M Maru; Asif Rashid; Russell Broaddus; Daoyan Wei; Mien-Chie Hung; Anil K Sood; Imad Shureiqi
Journal:  JCI Insight       Date:  2017-01-12

3.  iTRAQ based quantitative proteomics approach validated the role of calcyclin binding protein (CacyBP) in promoting colorectal cancer metastasis.

Authors:  Dipanjana Ghosh; Zhihan Li; Xing Fei Tan; Teck Kwang Lim; Yubin Mao; Qingsong Lin
Journal:  Mol Cell Proteomics       Date:  2013-03-29       Impact factor: 5.911

4.  Epigenetic Silencing of ALDH1L1, a Metabolic Regulator of Cellular Proliferation, in Cancers.

Authors:  Natalia V Oleinik; Natalia I Krupenko; Sergey A Krupenko
Journal:  Genes Cancer       Date:  2011-02

5.  Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer.

Authors:  Kejin Wu; Shuo Huang; Mingjie Zhu; Yunshu Lu; Jian Chen; Yongkun Wang; Qing Lin; Wei Shen; Shenglai Zhang; Jian Zhu; Y Eric Shi; Ziyi Weng
Journal:  Med Oncol       Date:  2013-05-22       Impact factor: 3.064

6.  Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression.

Authors:  Gustavo Ayala; Matteo Morello; Anna Frolov; Sungyong You; Rile Li; Fabiana Rosati; Gianluca Bartolucci; Giovanna Danza; Rosalyn M Adam; Timothy C Thompson; Michael P Lisanti; Michael R Freeman; Dolores Di Vizio
Journal:  J Pathol       Date:  2013-07-08       Impact factor: 7.996

7.  An exploratory analysis of γ-synuclein expression in endometrioid endometrial cancer.

Authors:  Jing Zou; Yujuan J Fan; Yaqing Q Meng; Hong Xu; Jiangtao Fan
Journal:  BMJ Open       Date:  2012-04-24       Impact factor: 2.692

8.  Gamma synuclein is a novel Twist1 target that promotes TGF-β-induced cancer cell migration and invasion.

Authors:  Ting Shao; Peiying Song; Hui Hua; Hongying Zhang; Xiangmin Sun; Qingbin Kong; Jiao Wang; Ting Luo; Yangfu Jiang
Journal:  Cell Death Dis       Date:  2018-05-24       Impact factor: 8.469

9.  Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer.

Authors:  Caiyun Liu; Bingbing Shi; Chonghua Hao; Qinghai Wang; Qiang Lv; Nianzeng Xing; Jianzhong Shou; Like Qu; Yanning Gao; Chao Qin; Jiyu Zhao; Chengchao Shou
Journal:  Oncotarget       Date:  2016-07-12

10.  Extracellular gamma-synuclein promotes tumor cell motility by activating β1 integrin-focal adhesion kinase signaling pathway and increasing matrix metalloproteinase-24, -2 protein secretion.

Authors:  Caiyun Liu; Like Qu; Chuanke Zhao; Chengchao Shou
Journal:  J Exp Clin Cancer Res       Date:  2018-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.